4502:TSETakeda Pharmaceutical Co. Ltd. Analysis

Takeda trades around ¥5,685, just below its 20‑day SMA of ¥5,686.65 but comfortably above the 50‑day (¥5,331) and 200‑day (¥4,604) averages, indicating a lingering bullish bias despite a bearish MACD histogram and signal. The RSI sits at 57, suggesting neutral‑to‑slightly‑positive momentum, while volatility is elevated at 21.7% over the past 30 days and beta is low at 0.32, implying limited market‑wide risk. Fundamentals reveal a PE of 80× versus an industry average of 25× and a forward PE of 40×, signaling significant overvaluation; the DCF fair value of ¥2,616 is far below the current price, and the dividend payout ratio of 280% raises sustainability concerns despite a 3.56% yield. Recent material news shows a 3.3% revenue dip due to Vyvanse’s loss of exclusivity and an earnings miss (EPS ¥0.215 vs ¥0.55 expected), yet a 6.7% uplift in growth‑and‑launch products and an upgraded FY2025 outlook point to a resilient pipeline. Analyst consensus remains “Buy” with a median target of ¥5,700, aligning closely with current levels and suggesting limited upside but a potential floor near the ¥5,491 support, just above the 20‑day SMA.